Drug Discovery Research
  • The Dahl lab is focused on the discovery and development of small molecule therapeutics targeting novel targets or mechanisms in the areas of neuroscience (neurodegeneration, addiction) and cancer. In addition, Dr. Dahl collaborates with other faculty members on various drug discovery projects, utilizing synthetic chemistry to develop structure-activity-relationships (SAR) to validate novel targets and enable preclinical optimization of candidate molecules (Russell Dahl).
  • Good DMPK properties along with minimal toxicity are critical for development of a successful drug candidate. Generally poor DMPK properties resulting in poor absorption, high clearance have been attributed to the failure of oral drugs during the clinical development. In addition, potential of drug interactions or their inadequate understanding can complicate successful drug development. The prediction of human pharmacokinetics and metabolism of drugs is critical to advance the right compounds into clinical settings. Though use of in vitro data to extrapolate in vivo has aided the effort allowing for prediction of pharmacokinetic parameters, the translation to a clinical outcome is far from accurate. Dr. Deshmukh's research is aimed at identifying  and studying  specific research problems in the area of  in vitro  DMPK and developing in silico tools  that can help improve the prediction of in vivo properties of potential drug candidates (Rahul Deshmukh)
  • Dr. Harrison's research is focused on the catalytic specificity of enzymes.  He uses X-ray crystallography, site-directed mutagenesis, and mechanistic enzymology to determine what keeps a reaction in an enzyme on pathway. He is also using X-ray crystallography to explore which inhibitor and enzyme properties contribute to molecular recognition (David Harrison).
  • Dr. Walters's research uses computational chemistry and computer modeling to search for new drug leads and to optimize existing leads. This project will provide opportunities for student research. (Eric Walters)
  • Development of antisense oligonucleotide technology as treatment for disease (Michelle Hastings).
Life in Discovery
Internal Funding Opportunities
3333 Green Bay Road, North Chicago, Il 60064-3095 • 847-578-3000